PD-L1 expression may elevate in a subset of metastatic clear cell renal cell carcinoma patients who are resistant to VEGFR-TKI, potentially through the mammalian target of rapamycin pathway (65). The gene discussed is KDR; the disease is clear cell renal carcinoma.